Monoclonal antibodies and Fc fragments for treating solid tumors

References

• KohlerGMilsteinCContinuous cultures of fused cells secreting antibody of predefined specificityNature197525655174954971172191
   PubMed Web of Science ®Google Scholar
• DillmanROPerceptions of Herceptin: a monoclonal antibody for the treatment of breast cancerCancer Biother Radiopharm199914151010850281
   PubMed Web of Science ®Google Scholar
• DillmanROMonoclonal antibodies for treating cancerAnn Intern Med198911175926032672932
   PubMed Web of Science ®Google Scholar
• DillmanROAntibodies as cytotoxic therapyJ Clin Oncol1994127149715158021742
   PubMed Web of Science ®Google Scholar
• WigzellHThe immune system as a therapeutic agentSci Am199326931261348211086
   PubMed Web of Science ®Google Scholar
• BoonTTeaching the immune system to fight cancerSci Am1993268382898316825
   PubMed Web of Science ®Google Scholar
• JiangHChessLRegulation of immune responses by T cellsN Engl J Med2006354111166117616540617
   PubMed Web of Science ®Google Scholar
• AbramowiczDCrusiauxAGoldmanMAnaphylactic shock after retreatment with OKT3 monoclonal antibodyN Engl J Med1992327107361495540
   PubMed Web of Science ®Google Scholar
• BajorinDFChapmanPBWongGYTreatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanomaMelanoma Res199225–63553621292783
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol19991792639264810561337
   PubMed Web of Science ®Google Scholar
• ChristiansenJRajasekaranAKBiological impediments to monoclonal antibody-based cancer immunotherapyMol Cancer Ther20043111493150115542788
   PubMed Web of Science ®Google Scholar
• BaselgaJTripathyDMendelsohnJPhase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancerSemin Oncol1999264 Suppl 12788310482197
   PubMed Web of Science ®Google Scholar
• SchechterALSternDFVaidyanathanLThe neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature198431259945135166095109
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• HeimannDMWeinerLMMonoclonal antibodies in therapy of solid tumorsSurg Oncol Clin N Am2007164775792viii18022544
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol200927567268019114685
   PubMed Web of Science ®Google Scholar
• HuangSMBockJMHarariPMEpidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neckCancer Res19995981935194010213503
   PubMed Web of Science ®Google Scholar
• VincenziBZoccoliAPantanoFVendittiOGalluzzoSCetuximab: from bench to bedsideCurr Cancer Drug Targets2010101809520088790
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med2004351433734515269313
   PubMed Web of Science ®Google Scholar
• Van CutsemEKohneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med2009360141408141719339720
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med2006354656757816467544
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalLancet Oncol2010111212819897418
   PubMed Web of Science ®Google Scholar
• VermorkenJBTrigoJHittROpen-label, uncontrolled, multi-center phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapyJ Clin Oncol200725162171217717538161
   PubMed Web of Science ®Google Scholar
• HardingJBurtnessBCetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibodyDrugs Today (Barc)200541210712715821783
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• SienaSPeetersMVan CutsemEAssociation of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumabBr J Cancer200797111469147418040272
   PubMed Web of Science ®Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol201028314706471320921462
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• WirthLJAllenAMPosnerMRPhase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neckAnn Oncol201021234234719892746
   PubMed Web of Science ®Google Scholar
• LacoutureMEMitchellEPPiperdiBSkin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancerJ Clin Oncol20102881351135720142600
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• SiebelsMRohrmannKObernederRA clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha- 2a in metastatic renal cell carcinoma patientsWorld J Urol201129112112620512580
   PubMed Web of Science ®Google Scholar
• MachielsJPSubramanianSRuzsaAZalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trialLancet Oncol201112433334321377930
   PubMed Web of Science ®Google Scholar
• O’DaySJHamidOUrbaWJTargeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignanciesCancer2007110122614262718000991
   PubMed Web of Science ®Google Scholar
• RibasAHauschildAKeffordAPhase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanomaJ Clin Oncol20082620 Suppl Abstract LBA9011
   Google Scholar
• KirkwoodJMLoriganPHerseyPPhase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanomaClin Cancer Res20101631042104820086001
   PubMed Web of Science ®Google Scholar
• WhiteAColemanRArmstrongDEfficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive, relapsed ovarian cancer subjects: final data from a multicenter phase II studyJ Clin Oncol20102815 Suppl Abstract 5001
   Web of Science ®Google Scholar
• ScheuerWFriessTBurtscherHBossenmaierBEndlJHasmannMStrongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor modelsCancer Res200969249330933619934333
   PubMed Web of Science ®Google Scholar
• LinkeRKleinASeimetzDCatumaxomab: clinical development and future directionsMAbs20102212913620190561
   PubMed Web of Science ®Google Scholar
• MaetzelDDenzelSMackBNuclear signalling by tumour-associated antigen EpCAMNat Cell Biol200911216217119136966
   PubMed Web of Science ®Google Scholar
• MunzMBaeuerlePAGiresOThe emerging role of EpCAM in cancer and stem cell signalingCancer Res200969145627562919584271
   PubMed Web of Science ®Google Scholar
• CarpenterGRedBMEpCAM: another surface-to-nucleus missileCancer Cell200915316516619249674
   PubMed Web of Science ®Google Scholar